A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007

This article is not included in any systematic review

This article is part of the following publication threads:
  • REFLEX [Randomised Evaluation oF Long-term Efficacy of rituXimab in RA] (5 documents)
Loading references information
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies. Patients will receive MabThera 1000mg i.v. on days 1 and 15, and methotrexate (10-25mg/week p.o. or parenteral), together with methylprednisolone 100mg i.v. prior to infusion of MabThera. After week 24, eligible patients may receive re-treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Epistemonikos ID: 3e983c1d585e3ae3188f7f9973f570e35a429806
First added on: Oct 09, 2017